154 related articles for article (PubMed ID: 37550494)
1. Prognostic utility of RECIP 1.0 with manual and AI-based segmentations in biochemically recurrent prostate cancer from [
Kendrick J; Francis RJ; Hassan GM; Rowshanfarzad P; Ong JS; McCarthy M; Alexander S; Ebert MA
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4077-4086. PubMed ID: 37550494
[TBL] [Abstract][Full Text] [Related]
2. Fully automatic prognostic biomarker extraction from metastatic prostate lesion segmentations in whole-body [
Kendrick J; Francis RJ; Hassan GM; Rowshanfarzad P; Ong JSL; Ebert MA
Eur J Nucl Med Mol Imaging; 2022 Dec; 50(1):67-79. PubMed ID: 35976392
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Performance of RECIP 1.0 Based on [
Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Higuchi T; Schlötelburg W; Michalski K; Gafita A; Rowe SP; Pomper MG; Buck AK; Werner RA
J Nucl Med; 2024 Apr; 65(4):560-565. PubMed ID: 38453363
[TBL] [Abstract][Full Text] [Related]
4. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.
Gafita A; Rauscher I; Fendler WP; Murthy V; Hui W; Armstrong WR; Herrmann K; Weber WA; Calais J; Eiber M; Weber M; Benz MR
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4271-4281. PubMed ID: 35767071
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Tumor Volume Assessment on PSMA PET After
Kind F; Eder AC; Jilg CA; Hartrampf PE; Meyer PT; Ruf J; Michalski K
J Nucl Med; 2023 Apr; 64(4):605-610. PubMed ID: 36302658
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study.
Gafita A; Rauscher I; Weber M; Hadaschik B; Wang H; Armstrong WR; Tauber R; Grogan TR; Czernin J; Rettig MB; Herrmann K; Calais J; Weber WA; Benz MR; Fendler WP; Eiber M
J Nucl Med; 2022 Nov; 63(11):1651-1658. PubMed ID: 35422442
[TBL] [Abstract][Full Text] [Related]
8. Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer.
Gafita A; Djaileb L; Rauscher I; Fendler WP; Hadaschik B; Rowe SP; Herrmann K; Calais J; Rettig M; Eiber M; Weber M; Benz MR; Farolfi A
Radiology; 2023 Jul; 308(1):e222148. PubMed ID: 37432081
[TBL] [Abstract][Full Text] [Related]
9. A convolutional neural network-based system for fully automatic segmentation of whole-body [
Jafari E; Zarei A; Dadgar H; Keshavarz A; Manafi-Farid R; Rostami H; Assadi M
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1476-1487. PubMed ID: 38095671
[TBL] [Abstract][Full Text] [Related]
10. Quantitative [
Kendrick J; Francis RJ; Hassan GM; Rowshanfarzad P; Ong JSL; Barry N; Rusanov B; Ebert MA
Sci Rep; 2023 Oct; 13(1):17673. PubMed ID: 37848692
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with
Murthy V; Gafita A; Thin P; Nguyen K; Grogan T; Shen J; Drakaki A; Rettig M; Czernin J; Calais J
J Nucl Med; 2023 Nov; 64(11):1737-1743. PubMed ID: 37678927
[TBL] [Abstract][Full Text] [Related]
12. Event-free survival after
Ceci F; Rovera G; Iorio GC; Guarneri A; Chiofalo V; Passera R; Oderda M; Dall'Armellina S; Liberini V; Grimaldi S; Bellò M; Gontero P; Ricardi U; Deandreis D
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3257-3268. PubMed ID: 35217883
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Role of
Lunger L; Chantadisai M; Karimzadeh A; Rauscher I; D'Alessandria C; Feuerecker B; Langbein T; Tauber R; Schiele S; Weber W; Eiber M
J Nucl Med; 2023 Jun; 64(6):896-901. PubMed ID: 36581373
[TBL] [Abstract][Full Text] [Related]
14.
Ceci F; Castellucci P; Graziani T; Farolfi A; Fonti C; Lodi F; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
[TBL] [Abstract][Full Text] [Related]
15. RECIP 1.0 Predicts Progression-Free Survival After [
Gafita A; Djaileb L; Rauscher I; Fendler WP; Hadaschik B; Rowe SP; Herrmann K; Solnes LB; Calais J; Rettig MB; Weber M; Farolfi A; Benz MR; Eiber M
J Nucl Med; 2024 Apr; ():. PubMed ID: 38637143
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Progression After
Soldatov A; von Klot CAJ; Walacides D; Derlin T; Bengel FM; Ross TL; Wester HJ; Derlin K; Kuczyk MA; Christiansen H; Henkenberens C
Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):95-104. PubMed ID: 30201438
[TBL] [Abstract][Full Text] [Related]
17. Prospective intra-individual blinded comparison of [
Pattison DA; Debowski M; Gulhane B; Arnfield EG; Pelecanos AM; Garcia PL; Latter MJ; Lin CY; Roberts MJ; Ramsay SC; Thomas PA
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):763-776. PubMed ID: 34383089
[TBL] [Abstract][Full Text] [Related]
18.
Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of negative
Celli M; De Giorgi U; Caroli P; Di Iorio V; Fantini L; Rossetti V; Foca F; Nicolini S; Giganti M; Paganelli G; Matteucci F
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):87-94. PubMed ID: 32588090
[TBL] [Abstract][Full Text] [Related]
20. Head-to-head comparisons of [
Ke ZB; Chen SM; Chen JY; Chen SH; You Q; Sun JB; Xue YT; Sun XL; Wu XH; Zheng QS; Wei Y; Xue XY; Xu N
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1240-1251. PubMed ID: 36416906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
